|
« Drug Companies Hide Side Effects From Investors As Well As Consumers |
Main
| Anaplastic Large Cell Lymphoma (ALCL) Linked to Breast Implants »
|
 |
|
General Electric Settles NSF Case on the Eve of Trial
|
At the last minute, General Electric settled a case brought by a plaintiff suffering from Nephrogenic Systemic Fibrosis (NSF). Trial was scheduled to begin today in U.S. District Court in Cleveland, Ohio, and would have been the first
NSF case to go to trial. A settlement was reached late Sunday night.
The plaintiff developed NSF in 2005, after receiving several scans during the previous two years using
Omniscan, GE’s brand of
gadolinium-based contrast agent.
Omniscan has caused more people to develop NSF than any other
gadolinium-based contrast agent.
NSF, also known as
nephrogenic fibrosing dermopathy (NFD), is an incurable disease characterized by hardening of the skin and other body tissues. The only known cause of NSF/NFD is the use of
gadolinium-based contrast agents in medical procedures such as MRI, MRA and CT scans (CAT scans).
|
|
|
|
|
|
|
Posted By DeCarli Law on
January 24, 2011 12:26 pm |
Permalink
|
|